Outlook Therapeutics Corp (OTLK) - מקדם חוב לטווח ארוך להון

Lytenava patents create significant barriers to entry, which correlates with the long-term financial leverage ratio dynamics, where the latest parameter is 0.00. The environmental strategy of Outlook Therapeutics (OTLK) is based on the safe disposal of chemicals. Current management is adapting clinical plans to meet FDA requirements, which drives the volatility of investor confidence in this biotech.

This indicator measures the proportion of long-term liabilities within the equity structure, determining the company's degree of financial leverage. Analyzing this metric allows for an assessment of the company's resilience to long-term credit risks. The dynamics of the long-term debt-to-equity ratio reflect the balance between debt financing and business autonomy. For Outlook Therapeutics (OTLK), this is critical due to the absence of revenue and the costs associated with drug certification. An increase in this ratio signals attempts to cover cash flow gaps through external loans.